ProShare Advisors LLC Buys 49,430 Shares of Boston Scientific Corporation $BSX

ProShare Advisors LLC raised its stake in shares of Boston Scientific Corporation (NYSE:BSX) by 20.8% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 286,725 shares of the medical equipment provider’s stock after purchasing an additional 49,430 shares during the quarter. ProShare Advisors LLC’s holdings in Boston Scientific were worth $30,797,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. 1248 Management LLC bought a new position in Boston Scientific in the first quarter worth about $26,000. Y.D. More Investments Ltd purchased a new position in shares of Boston Scientific during the 1st quarter worth approximately $27,000. Sound Income Strategies LLC grew its holdings in shares of Boston Scientific by 90.9% during the 2nd quarter. Sound Income Strategies LLC now owns 252 shares of the medical equipment provider’s stock worth $27,000 after acquiring an additional 120 shares during the period. Princeton Global Asset Management LLC purchased a new position in shares of Boston Scientific in the 2nd quarter valued at approximately $32,000. Finally, Oliver Lagore Vanvalin Investment Group bought a new stake in shares of Boston Scientific during the second quarter valued at approximately $37,000. 89.07% of the stock is owned by hedge funds and other institutional investors.

Boston Scientific Stock Up 1.6%

NYSE:BSX opened at $102.53 on Wednesday. The company has a debt-to-equity ratio of 0.49, a quick ratio of 0.82 and a current ratio of 1.37. The firm has a market cap of $151.99 billion, a P/E ratio of 54.83, a P/E/G ratio of 2.02 and a beta of 0.58. Boston Scientific Corporation has a fifty-two week low of $85.98 and a fifty-two week high of $109.50. The firm has a 50-day simple moving average of $99.92 and a two-hundred day simple moving average of $102.53.

Boston Scientific (NYSE:BSX) last issued its earnings results on Wednesday, October 22nd. The medical equipment provider reported $0.75 EPS for the quarter, beating the consensus estimate of $0.71 by $0.04. Boston Scientific had a return on equity of 19.74% and a net margin of 14.43%.The business had revenue of $5.07 billion for the quarter, compared to the consensus estimate of $4.97 billion. During the same period last year, the business posted $0.63 EPS. The company’s revenue was up 20.3% compared to the same quarter last year. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS. Q4 2025 guidance at 0.770-0.790 EPS. Analysts predict that Boston Scientific Corporation will post 2.85 earnings per share for the current fiscal year.

Insider Activity

In other news, EVP Joseph Michael Fitzgerald sold 50,000 shares of Boston Scientific stock in a transaction that occurred on Monday, November 3rd. The shares were sold at an average price of $99.47, for a total value of $4,973,500.00. Following the completion of the sale, the executive vice president directly owned 178,342 shares in the company, valued at $17,739,678.74. The trade was a 21.90% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Ellen M. Zane sold 12,891 shares of the business’s stock in a transaction that occurred on Thursday, November 6th. The shares were sold at an average price of $98.28, for a total transaction of $1,266,927.48. Following the transaction, the director directly owned 24,134 shares of the company’s stock, valued at $2,371,889.52. The trade was a 34.82% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 175,782 shares of company stock valued at $17,742,314 over the last quarter. 0.50% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on BSX shares. Robert W. Baird increased their price objective on Boston Scientific from $123.00 to $128.00 and gave the stock an “outperform” rating in a report on Wednesday, October 1st. Morgan Stanley upped their target price on shares of Boston Scientific from $125.00 to $130.00 and gave the stock an “overweight” rating in a research report on Thursday, October 23rd. Wells Fargo & Company lifted their price target on shares of Boston Scientific from $124.00 to $125.00 and gave the company an “overweight” rating in a research report on Thursday, October 23rd. Weiss Ratings reissued a “buy (b-)” rating on shares of Boston Scientific in a research note on Wednesday, October 8th. Finally, UBS Group upped their price objective on shares of Boston Scientific from $135.00 to $140.00 and gave the stock a “buy” rating in a report on Thursday, October 23rd. Two analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average price target of $123.77.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.